If the trial can ensure that the participant are no less likely to be exposed to COVD-19, and we assume that the benefits and safety of tronfinetide are in line with the phase 2 trail results. (relating the fewer breathing problem). You could argue that participants may be "safer" receiving trofinetide than not. Simplistic argument I know, but why would you stop the trial?
Across the core efficacy measures, improvement was seen in clinically important symptom areas core to RTT: breathing problems, repetitive movements (including hand function), mood dysfunction (including nighttime behaviors), ambulation, and seizures. On the RSBQ, based on comparison with placebo and Cohen d effect sizes (figure 4A), all of the subscales except one were directionally in favor of the 200 mg/kg bid treatment group with notable improvement in mood dysfunction and disruptive behavior (General Mood subscale, p = 0.007), breathing problems (Breathing subscale p = 0.095), and repetitive movements (Repetitive Face Movement subscale, p = 0.047).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)